IVIg vs placebo or no treatment
Overall survival (risk of death) ‐ adults with myocarditis, median · adults with acute myocarditis
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ adults with myocarditis, median compared with placebo or no treatment (very low certainty).
1 finding from 1 review
- Intravenous immunoglobulin for presumed viral myocarditis in children and adults 2020 · Cochrane Headline outcomes onlyRR 0.91 [0.23, 3.62]2 studies · 103 participantsVery low